

Ovarian Cancer Staging by MDCT

Mahrooz Malek^{1,*}

¹Assistant professor of Tehran University of Medical Sciences, Tehran, Iran

*Corresponding author: Mahrooz Malek, Assistant professor of Tehran University of Medical Sciences, Tehran, Iran. E-mail: mahrooz.malek@gmail.com

Received 2016 December 21; **Accepted** 2017 February 08.

Abstract

Ovarian cancer is the most lethal gynecological cancer and about 70% of the patients are advanced stage in the time of diagnosis. Decision about management (surgical debulking versus neoadjuvant chemotherapy) in ovarian cancer patients is dependent on initial staging by abdominopelvic MDCT or MRI, so, Radiologist expertise on ovarian cancer staging is very important. Involvement of mesenteric root, peritoneal implants larger than 2 cm, lymphadenopathy superior to renal hilum and implants near hepatic veins are criteria for nonresectability of ovarian cancer and radiologist must be familiar and expert on the imaging protocol and findings on MDCT for ovarian cancer staging.

This is an abstract presented in the 33rd Iranian congress of radiology (ICR) and the 15th congress of Iranian radiographic science association (IRSA).